Highlights Newsletter 1

This newsletter presents you the following key sessions:

1. PODCAST with prof. dr. Pieter Sonneveld about VRD consolidation treatment followed by maintenance therapy in
    transplant-eligible patients with multiple myeloma

2. Haematopoietic cell transplantation also recommended in older patients with advanced high-risk myelodysplastic
    syndrome with a suitable donor

3. CRISPR-based gene editing with CTX001 as a potential functional cure for transfusion-dependent β-thalassemia
    and sickle cell disease

4. Ruxolitinib outperforms the current best available therapy for patients with steroid-refractory/dependent chronic
    graft-versus-host disease

5. Subcutaneous daratumumab plus pomalidomide-dexamethasone: an effective and convenient treatment option
    for patients with relapsed/refractory multiple myeloma